Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 1
1993 2
1994 1
1996 1
1997 1
1998 1
1999 1
2001 1
2002 2
2005 1
2007 1
2011 1
2012 1
2013 3
2014 3
2015 1
2016 1
2017 2
2018 1
2019 1
2020 4
2021 2
2022 1
2023 2
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
Denkert C, Seither F, Schneeweiss A, Link T, Blohmer JU, Just M, Wimberger P, Forberger A, Tesch H, Jackisch C, Schmatloch S, Reinisch M, Solomayer EF, Schmitt WD, Hanusch C, Fasching PA, Lübbe K, Solbach C, Huober J, Rhiem K, Marmé F, Reimer T, Schmidt M, Sinn BV, Janni W, Stickeler E, Michel L, Stötzer O, Hahnen E, Furlanetto J, Seiler S, Nekljudova V, Untch M, Loibl S. Denkert C, et al. Among authors: stotzer o. Lancet Oncol. 2021 Aug;22(8):1151-1161. doi: 10.1016/S1470-2045(21)00301-6. Epub 2021 Jul 9. Lancet Oncol. 2021. PMID: 34252375
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials.
Wasan HS, Gibbs P, Sharma NK, Taieb J, Heinemann V, Ricke J, Peeters M, Findlay M, Weaver A, Mills J, Wilson C, Adams R, Francis A, Moschandreas J, Virdee PS, Dutton P, Love S, Gebski V, Gray A; FOXFIRE trial investigators; SIRFLOX trial investigators; FOXFIRE-Global trial investigators; van Hazel G, Sharma RA. Wasan HS, et al. Lancet Oncol. 2017 Sep;18(9):1159-1171. doi: 10.1016/S1470-2045(17)30457-6. Epub 2017 Aug 3. Lancet Oncol. 2017. PMID: 28781171 Free PMC article. Clinical Trial.
Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study.
Lüftner D, Schuetz F, Schneeweiss A, Hartkopf A, Bloch W, Decker T, Uleer C, Stötzer O, Foerster F, Schmidt M, Mundhenke C, Tesch H, Jackisch C, Fischer T, Kreuzeder J, Guderian G, Fasching PA. Lüftner D, et al. Among authors: stotzer o. Int J Cancer. 2024 Jul 1;155(1):128-138. doi: 10.1002/ijc.34912. Epub 2024 Mar 6. Int J Cancer. 2024. PMID: 38447007
Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial.
Blohmer JU, Link T, Reinisch M, Just M, Untch M, Stötzer O, Fasching PA, Schneeweiss A, Wimberger P, Seiler S, Huober J, Thill M, Jackisch C, Rhiem K, Solbach C, Hanusch C, Seither F, Denkert C, Engels K, Nekljudova V, Loibl S; GBG and AGO-B. Blohmer JU, et al. Among authors: stotzer o. JAMA Oncol. 2022 Jul 1;8(7):1010-1018. doi: 10.1001/jamaoncol.2022.1059. JAMA Oncol. 2022. PMID: 35588050 Free PMC article. Clinical Trial.
RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial.
Link T, Blohmer JU, Schmitt WD, Kuhlmann JD, Just M, Untch M, Stotzer O, Fasching PA, Thill M, Reinisch M, Schneeweiss A, Wimberger P, Seiler S, Huober J, Jackisch C, Rhiem K, Hanusch C, Sinn BV, Nekljudova V, Loibl S, Denkert C. Link T, et al. Among authors: stotzer o. Clin Cancer Res. 2023 Nov 14;29(22):4606-4612. doi: 10.1158/1078-0432.CCR-23-1801. Clin Cancer Res. 2023. PMID: 37725572
The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy.
Wimberger P, Blohmer JU, Krabisch P, Link T, Just M, Sinn BV, Simon E, Solbach C, Fehm T, Denkert C, Kühn C, Rhiem K, Tesch H, Kümmel S, Petzold A, Stötzer O, Meisel C, Kuhlmann JD, Nekljudova V, Loibl S. Wimberger P, et al. Among authors: stotzer o. Breast Cancer Res. 2023 Mar 28;25(1):32. doi: 10.1186/s13058-023-01619-2. Breast Cancer Res. 2023. PMID: 36978142 Free PMC article. Clinical Trial.
Nivolumab in HIV-related non-small-cell lung cancer.
Hentrich M, Schipek-Voigt K, Jäger H, Schulz S, Schmid P, Stötzer O, Bojko P. Hentrich M, et al. Among authors: stotzer o. Ann Oncol. 2017 Nov 1;28(11):2890. doi: 10.1093/annonc/mdx321. Ann Oncol. 2017. PMID: 29106466 Free article. No abstract available.
[Allogeneic transplantation in malignant lymphoma].
Stötzer OJ, Schleuning M, Ledderose G, Hiddemann W, Kolb HJ. Stötzer OJ, et al. Dtsch Med Wochenschr. 2001 Sep 28;126(39):1062-9. doi: 10.1055/s-2001-17492. Dtsch Med Wochenschr. 2001. PMID: 11602913 German.
High-risk additional chromosomal abnormalities at low blast counts herald death by CML.
Hehlmann R, Voskanyan A, Lauseker M, Pfirrmann M, Kalmanti L, Rinaldetti S, Kohlbrenner K, Haferlach C, Schlegelberger B, Fabarius A, Seifarth W, Spieß B, Wuchter P, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Burchert A, Brümmendorf TH, Hasford J, Hochhaus A, Saußele S, Baccarani M; SAKK and the German CML Study Group. Hehlmann R, et al. Leukemia. 2020 Aug;34(8):2074-2086. doi: 10.1038/s41375-020-0826-9. Epub 2020 May 7. Leukemia. 2020. PMID: 32382082 Free PMC article.
37 results